SCHEMBL15021185

SCHEMBL15021185

O=C(O)NC1CCN(Cc2ccc(C(=O)NCCc3cccnc3)cc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 3/20 0.61
DRD4 P21917 1/20 0.60
SLC6A5 Q9Y345 1/20 0.56
CHRM4 P08173 1/20 0.56
CYP2D6 P10635 2/20 0.55
MCHR1 Q99705 2/20 0.55
CHRM1 P11229 1/20 0.55
HTR2A P28223 1/20 0.55
TMEM97 Q5BJF2 2/20 0.55
SLC6A12 P48065 1/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2C9 P11712 1/20 0.55
TSHR P16473 1/20 0.55
MAPK1 P28482 1/20 0.55
CYP2C19 P33261 1/20 0.55
PRKAB2 O43741 1/20 0.55
PRKAG1 P54619 1/20 0.55
PRKAA2 P54646 1/20 0.55
PRKAA1 Q13131 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15020876 0.87 CHRM4 (0.56) SIGMAR1DRD4SLC6A5CHRM4MEN1
SCHEMBL62237 0.86 DRD4 (0.76) SIGMAR1DRD4SLC6A5CYP2D6MCHR1
SCHEMBL14082514 0.80 DRD4 (0.71) SIGMAR1DRD4CYP2D6MCHR1TMEM97
SCHEMBL61489 0.78 SIGMAR1 (0.72) SIGMAR1DRD4CYP2D6MCHR1TMEM97
SCHEMBL7656471 0.78 SIGMAR1 (0.65) SIGMAR1DRD4SLC6A5CHRM1MAPK1
SCHEMBL61848 0.77 TMEM97 (0.83) SIGMAR1DRD4CYP2D6MCHR1TMEM97
SCHEMBL8228250 0.76 SMN1; SMN2 (0.56) CYP2D6CYP3A4TSHRMEN1KMT2A
SCHEMBL4662136 0.76 RAB9A (0.83) CYP2C9CYP2C19MEN1KMT2ASMN1; SMN2
SCHEMBL2425554 0.75 SIGMAR1 (0.78) SIGMAR1DRD4CYP2D6MCHR1TMEM97
SCHEMBL14456862 0.75 ACHE (0.66) CHRM4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2794595-B1 HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INT (DE) 2017-08-02 EP disclosed
EP-2794595-A1 HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF Boehringer Ingelheim International GmbH (DE) 2014-10-29 EP disclosed
US-8859559-B2 Substituted pyrazines and their use in the treatment of disease BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-14 US disclosed
WO-2013092674-A1 HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-27 WO disclosed
US-20130157981-A1 HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130157981-A1 HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF SCNN1B, SCNN1A, TRPM5 SIGMAR1 2242/4885DRD4 3728/4885SLC6A5 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.